Close Menu

NEW YORK – Chugai Pharmaceutical, a subsidiary of Roche, announced today that Japan's Ministry of Health, Labour, and Welfare has granted additional approval of Foundation Medicine's FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for entrectinib (Roche's Rozlytrek), marketed in Japan by Chugai.

The drug is for treating neurotrophic tyrosine receptor kinase fusion-positive solid tumors. It is a ROS1/TRK inhibitor and has been approved for treating adult and pediatric patients with NTRK fusion-positive advanced and recurrent solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.